



(12) **United States Patent**
Simon

(10) **Patent No.:** **US 9,409,996 B2**
(45) **Date of Patent:** ***Aug. 9, 2016**

(54) **TREATMENT OF FOOD INTOLERANCE AND FOOD ALLERGY WITH IGM**

(71) Applicant: **Michael R. Simon**, Ann Arbor, MI (US)

(72) Inventor: **Michael R. Simon**, Ann Arbor, MI (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/014,200**

(22) Filed: **Feb. 3, 2016**

(65) **Prior Publication Data**

US 2016/0145353 A1 May 26, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/264,053, filed on Apr. 28, 2014, now Pat. No. 9,273,129, which is a continuation of application No. 13/214,952, filed on Aug. 22, 2011, now Pat. No. 8,709,413, which is a continuation-in-part of application No. 12/138,758, filed on Jun. 13, 2008, now Pat. No. 8,021,645, which is a continuation-in-part of application No. 11/851,606, filed on Sep. 7, 2007, now Pat. No. 7,794,721, which is a continuation of application No. 11/839,781, filed on Aug. 16, 2007, now Pat. No. 7,597,891, which is a continuation-in-part of application No. 11/610,154, filed on Dec. 13, 2006, now abandoned.

(51) **Int. Cl.**

A61K 39/395 (2006.01)
C07K 16/44 (2006.01)
A61K 39/00 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 16/44** (2013.01); **A61K 2039/505** (2013.01)

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,190,752	A	3/1993	Moller et al.	
5,773,000	A	6/1998	Bostwick et al.	424/167.1
6,162,904	A	12/2000	Mamidi et al.	
6,932,967	B2	8/2005	Simon	424/130.1
6,967,106	B2	11/2005	Simon	436/513
7,186,410	B2	3/2007	Chtourou et al.	
8,709,413	B2 *	4/2014	Simon	C07K 16/16 412/130.1
9,273,129	B2 *	3/2016	Simon	C07K 16/00

FOREIGN PATENT DOCUMENTS

WO	WO 03/015817	2/2003	A61K 39/395
WO	WO 2009/139624 A1	11/2009	C07K 16/04

OTHER PUBLICATIONS

Alfrede E. Bacon, III et al., Immunoglobulin G. Directed Against Toxins A and B of Clostridium Difficile in The General population and Patients with Abtibioteice-Associated Diarrhea, 1994, pp. 205-209, DIAGN Microbiol Infect Dis.

L.A. Barroso et al; Nucleotide Sequence of Clostridium Difficile Toxin B Gene; Nucleic Acids Reasearch, vol. 18, No. 13; 1990; Oxford University Press.

Jay A. Berzofsky, et al., Antigen-Antibody Interactions and Monoclonal Antibodies; Fundamental Immunology, Third Edition; 1993; pp. 421, 455-464; Raven Press Ltd., New York.

Mary Boesman-Finkelstein, et al.; Bovine Lactogenic Immunity Against Cholera Toxin-Related Enterotoxins and Vibrio Cholerae Outer Membranes; Infection and Immunity; 1989; pp. 1227-1234; American Society of Microbiology.

Harald Brussow et al., Bovine Milk Immunoglobulins for Passive Immunity to Infantile Rotavirus Gastroenteritis, Journal of Clinical Microbiology, Jun. 1987; pp. 982-986; American Society for Microbiology.

Lawrence A. Cone, MD et al., A Durable Response to Relapsing Clostridium Difficile Colitis May Require Combined Therapy and High-dose Oral Vancomycin and Intravenous Immune Globulin; Infectious Diseases in Clinical Practice; vol. 4, No. 4, 2007; pp. 217-220.

B. Corthesy; Recombinant Secretary IgA for Immune Intervention Against Mucosal Pathogens; Immunoglobulins and Mechanisms of Mucosal Immunity; Biochem Soc. Trans; 1997; 471-475.

G. Corthier et al., Emergence in Gnotobiotic Mice of Nontoxigenic Clones of Clostridium Difficile from a Toxinogenic One; Infection and Immunity, Jun. 1988; pp. 1500-1504; vol. 56, No. 6.

G. Corthier et al., Protection Against Experimental Pseudomembranous Colitis in Gnotobiotic Mice by Use of Monoclonal Antibodies Against Clostridium Difficile Toxin A; Infection and Immunity, Mar. 1991, pp. 1192-1195; vol. 59, No. 3.

Pascal Crottet et al; Expression, Purification Biochemical Characterization of Recombinant Murine Secretary Component: A Novel Tool in Mucosal Immunology; Biochem Society J; 1999; pp. 299-306.

C.H. Dove et al.; Molecular Characterization of the Clostridium Difficile Toxin A Gene, Infection and Immunity; Feb. 1990; pp. 480-488; vol. 58, No. 2.

Marion Ehrich et al.; Production of Clostridium Difficile Antitoxin; Infection and Immunity; Jun. 1980; pp. 1041-1043; vol. 28, No. 3.

Ronald Fayer et al.; Immunotherapeutic Efficacy of Bovine Colostral Immunoglobulins from a Hyperimmunized Cow against Cryptosporidiosis in Neonatal Mice; Infection and Immunity, Sep. 1990; pp. 2962-2965; vol. 58, No. 9.

Dale N. Gerding; Clostridium Difficile-Associated Diarrhea and Colitis in Adults; A Prospective Case-Controlled Epidemiologic Study, Arch Intern Med; vol. 146, Jan. 1986.

(Continued)

Primary Examiner — Nora Rooney

(74) Attorney, Agent, or Firm — Avery N. Goldstein; Blue Filament Law PLLC

(57) **ABSTRACT**

A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.

9 Claims, No Drawings